lower gastrointestinal disease with surgical indication (regardless of benign or malignant) lower gastrointestinal infection, intra-abdominal infection
Conditions
Interventions
Cefmetazole, flomoxef or ceftolozane-tazobactam + metronidazole is administered intravenously as a prophylactic antibiotics for elective lower gastrointestinal surgery. Each drug is administered just
lower gastrointestinal surgery, intra-abdominal infection, cefmetazole, flomoxef, ceftolozane-tazobactam, metronidazole
Sponsors
Ohge Hiroki
Yoshimura Kosuke
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1 Patients scheduled for elective lower gastrointestinal surgery (regardless of open surgery or laparoscopic surgery) gastrointestinal surgery (limited to open surgery cases) 2 Inpatients over 20 years old (include 20 years old) who agree to participate in this study, regardless of gender 3 Patients who can give written informed consent to participate in this study
Exclusion criteria
Exclusion criteria: 1 Patients with a history of allergies to Cefmetazole, Flomoxef, Ceftolozane/Tazobactam or Metronidazole 2 Patients with a history of allergies to cephems 3 Combined use of 4 Patients who are pregnant or nursing 5 Patients with organic diseases in the brain and spinal cord 6 Patients with renal dysfunction who have creatinine clearance less than 50 ml / min estimated by Cockloft-Gault equation 7 Patients judged inappropriate for this study by the researcher
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Pharmacokinetic parameters (Cmax, AUC, T1/2, Tmax) of each drug in plasma, peritoneal fluid and abdominal tissues (peritoneum and subcutaneous adipose tissue) | — |
Contacts
Public ContactKosuke Yoshimura
Hiroshima University graduate school
Outcome results
None listed